News

Wegovy uses the same active ingredient (semaglutide ... dosing for weight loss and diabetes management, and how does it differ from Wegovy's? Experts weighed in, and we provided an Ozempic dosing ...
Single dose of Vivani’s NPM-139 semaglutide implant led to nearly 20% weight loss in rats, suggesting once- or twice-yearly dosing. NPM-139 showed steady semaglutide release with potential for ...
"With the FDA announcing the resolution of shortages for Semaglutide (Wegovy, Ozempic) and Tirzepatide (Zepbound, Mounjaro), compounding pharmacies must halt production of these medications. This ...
NPM-139 treatment resulted in nearly 20% placebo-adjusted weight loss from a single administration with expected once or twice-yearly dosing NPM ... containing semaglutide generated $25 billion ...
NanoPortalâ„¢ technology successfully delivers semaglutide, the active ingredient ... administration with expected once or twice-yearly dosing NPM-139 is a miniature, subdermal implant in ...